Part 2: Chronic Lymphocytic Leukemia

Kami J. Maddocks, MD

Assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH

Samantha M. Jaglowski, MD

Assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH

Question 4

You decide to treat the patient in Question 1. You perform risk stratification and find that she has unmutated IGVH and del(17p13) on FISH. On physical exam, she does not have any palpable lymphadenopathy greater than 3 cm. Which of the following would NOT be an appropriate front-line treatment option?

  •   Fludarabine, cyclophosphamide, and rituximab
  •   Single-agent ofatumumab
  •   Single-agent alemtuzumab
  •   Fludarabine and rituximab

Updated 08/17/2012 • jdw | Copyright ©2014 Turner White Communications